Mendeley出力
＜学術雑誌論文＞
Ｂ型肝炎ウイルスの再活性化の現状
| 作成者 | |
|---|---|
| 本文言語 | |
| 出版者 | |
| 発行日 | |
| 収録物名 | |
| 巻 | |
| 号 | |
| 開始ページ | |
| 終了ページ | |
| 出版タイプ | |
| アクセス権 | |
| JaLC DOI | |
| 概要 | Globally, it is estimated that around 1 in every 3 individuals may have been exposed to hepatitis B virus(HBV) infection. In addition, population of 6％ are chronic carriers and over 600,000 people die... each year from acute hepatitis, liver cirrhosis or hepatocellular carcinoma due to HBV infection. Recently, HBV reactivation associated with immune-suppressive and biological therapies is emerging to be an important cause of morbidity and mortality in patients with prior exposure to HBV infection. With the advent of newer and emerging forms of cancer chemotherapy, immunosuppressive or biologic therapies, it has become important to understand the mechanisms whereby certain therapies are more prone to HBV reactivation. In this article, we summarize the mechanism of HBV reactivation associated with immune-suppressive and biological therapies.続きを見る |
| 目次 | はじめに 1．B型肝炎の再活性化の病態・概要 2．国内外でのＢ型肝炎再活性化に対する対策 3．九州大学病院における現状と独自の対策 おわりに |
詳細
| PISSN | |
|---|---|
| NCID | |
| レコードID | |
| 査読有無 | |
| 主題 | |
| タイプ | |
| 登録日 | 2019.05.21 |
| 更新日 | 2021.03.03 |